Asthma and Atopic March Syndrome caused by GMOs? Science says ‘No’ – Genetic Literacy Project


Genetic Literacy Project

Asthma and Atopic March Syndrome caused by GMOs? Science says 'No'
Genetic Literacy Project
Asthma is a worldwide problem, afflicting more than 230 million people around the globe. It's particularly a problem with children, sending 775,000 of them to the emergency room every year in the United States. It's also more prevalent in

View full post on asthma – Google News

Asthma and Atopic March Syndrome caused by GMOs? Independent science … – Genetic Literacy Project


Genetic Literacy Project

Asthma and Atopic March Syndrome caused by GMOs? Independent science
Genetic Literacy Project
Asthma is a worldwide problem, afflicting more than 230 million people around the glove. It's particularly a problem with children, sending 775,000 of them to the emergency room every year in the United States. It's also more prevalent in

View full post on asthma – Google News

[Updating the concept of asthma. Is asthma a syndrome?].

Related Articles

[Updating the concept of asthma. Is asthma a syndrome?].

Rev Alerg Mex. 2015 Apr-Jun;62(2):134-41

Authors: Muñoz-López F

Abstract
Several symptoms are common to different processes that affect the respiratory system and their precise assessment is key to a correct diagnosis. Amongst those symptoms, mostly dyspnoea oriented toward the possible diagnosis of asthma. Nevertheless, the concept of asthma has changed in recent times, as inflammation of the bronchial tree is valued as the pathogenic base of the process, although it can not be ignored that the bronchial hyperresponsiveness is still the basis of dyspnoea crisis. In the last years, several variants have been established, being defined as phenotypes and endotypes that can identify diverse asthmatic or pseudo-asthmatic processes, and there for it is questioned if asthma is not the only process, but a syndrome. In any case, it cannot be ignored that dyspnoea episodes can be based on bronchial hyperresponsiveness of genetic origin or due to inflammation because of unfavourable environmental conditions, as well as physical exercise or the ingestión of aspirin, processes in which other mechanisms are involved.

PMID: 25958377 [PubMed – in process]

View full post on pubmed: asthma

Risk of idiopathic nephrotic syndrome among children with asthma: a nationwide … – Nature.com

Risk of idiopathic nephrotic syndrome among children with asthma: a nationwide
Nature.com
Although clinical and immunological studies have shown a possible link between allergy and idiopathic nephrotic syndrome (INS), the nature of the relationship remains unclear. Asthma is the most common chronic allergic airway inflammation. However, no …

View full post on asthma – Google News

Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease.

Related Articles

Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease.

Cochrane Database Syst Rev. 2014 Aug 2;8:CD003733

Authors: Knight-Madden JM, Hambleton IR

Abstract
BACKGROUND: Bronchodilators are used to treat bronchial hyper-responsiveness in asthma. Bronchial hyper-responsiveness may be a component of acute chest syndrome in people with sickle cell disease. Therefore, bronchodilators may be useful in the treatment of acute chest syndrome.
OBJECTIVES: To assess the benefits and risks associated with the use of bronchodilators in people with acute chest syndrome.
SEARCH METHODS: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches, handsearches of relevant journals and abstract books of conference proceedings. Additional searches were carried out on MEDLINE (1966 to 2002) and Embase (1981 to 2002).Date of the most recent search of the Group’s Haemoglobinopathies Trials Register: 17 March 2014.
SELECTION CRITERIA: Randomised or quasi-randomised controlled trials. Trials using quasi-randomisation methods will be included in future updates of this review if there is sufficient evidence that the treatment and control groups are similar at baseline.
DATA COLLECTION AND ANALYSIS: We found no trials investigating the use of bronchodilators for acute chest syndrome in people with sickle cell disease.
MAIN RESULTS: We found no trials investigating the use of bronchodilators for acute chest syndrome in people with sickle cell disease.
AUTHORS’ CONCLUSIONS: If bronchial hyper-responsiveness is an important component of some episodes of acute chest syndrome in people with sickle cell disease, the use of inhaled bronchodilators may be indicated. There is need for a well-designed, adequately-powered randomised controlled trial to assess the benefits and risks of the addition of inhaled bronchodilators to established therapies for acute chest syndrome in people with sickle cell disease.

PMID: 25086371 [PubMed – as supplied by publisher]

View full post on pubmed: asthma